Virosome studied by MedImmune

By Dylan Bushell-Embling
Friday, 18 July, 2008

Technology developed by Norwood Abbey's [ASX: NAL] second-tier subsidiary Virosome Biologicals is being evaluated by US company MedImmune.

The companies have signed a six-month exclusive evaluation agreement over Virosome's virosomal vaccine technology. In this time the companies will collaborate on research using the virosome technology with MedImmune vaccine candidates.

MedImmune is a member of the AstraZeneca group.

Scientists uncover how cancer cells hide from immune system

By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...

Vanillin flavouring in vapes may disrupt embryo development

Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...

Heart valve tissues created from stem cells

The breakthrough should help advance our understanding into how human heart valves develop,...

Content from other channels on our network

UTS pilot project to mitigate methane emissions

Government invests $1.5m in regional science partnerships

Desalination marine works conclude at Belmont

Zip Water releases 2025 Sustainability Report

Australia's EV fleet transition will be won or lost at the depot

Engineers Australia supports national engineer registration

Asahi to use recycled material for all plastic soft drink bottles

Queensland Government and CSIRO launch free R&D program for SMEs

Applications open in WA for submarine sustainment contracts

Construction begins on WA gallium project

Sale of Hobart Private Hospital to Calvary raises concerns

Opinion: The growing risk of AI-driven self-diagnosis in breast health

A new national approach to clinical governance

Opinion: The debate over the government's aged care algorithm is missing the point

Commonwealth Home Support Program extended to 30 June 2029